Meridian Bioscience Inc   (VIVO)
Other Ticker:  
Price: $33.9700 $0.00 0.000%
Day's High: $34.02 Week Perf: 0.62 %
Day's Low: $ 33.93 30 Day Perf: 2.2 %
Volume (M): 6,423 52 Wk High: $ 34.02
Volume (M$): $ 218,183 52 Wk Avg: $32.57
Open: $33.95 52 Wk Low: $31.14

 Market Capitalization (Millions $) 1,491
 Shares Outstanding (Millions) 44
 Employees 850
 Revenues (TTM) (Millions $) 302
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 10

Meridian Bioscience Inc
Meridian Bioscience Inc.
is a US-based company that specializes in the development, manufacturing, and distribution of diagnostic test kits, reagents, and related products for the healthcare industry.
The company's main product lines include gastrointestinal, respiratory, and viral and parasitic infection diagnostic test kits, as well as molecular diagnostic tests.
Meridian Bioscience Inc.
was founded in 1976 and is headquartered in Cincinnati, Ohio.
The company's mission is to improve global human health by providing innovative and high-quality diagnostic solutions.
Meridian Bioscience Inc.
is a publicly traded company, listed on the NASDAQ stock exchange under the ticker symbol VIVO.
The company operates through two main segments: Diagnostics and Life Science.
The Diagnostics segment primarily focuses on the development, manufacturing, and distribution of diagnostic test kits for gastrointestinal, respiratory, and viral and parasitic infection diagnostics.
The Life Science segment focuses on providing molecular diagnostic reagents, including RNA and DNA extraction kits and fluorescent dyes for research and clinical applications.
Meridian Bioscience Inc.
serves customers in more than 70 countries worldwide, including hospitals, reference laboratories, research institutes, and physician offices.
The company has established partnerships with leading healthcare organizations and diagnostic companies to expand its product portfolio and to advance healthcare solutions.
In addition, the company has invested heavily in research and development activities to diversify its product offerings and to stay at the forefront of diagnostic innovation.
Overall, Meridian Bioscience Inc.
has developed a reputation as a trusted supplier of quality diagnostic products and as an innovator in the diagnostic industry.

   Company Address: 3471 River Hills Drive Cincinnati 45244 OH
   Company Phone Number: 271-3700   Stock Exchange / Ticker: NASDAQ VIVO
   VIVO is expected to report next financial results on November 21, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Meridian Bioscience Inc

VIVO has Slipped into deficit at the In Vitro and In Vivo Diagnostic Substances company all along the fiscal first quarter of 2023

Meridian Bioscience Inc reported disappointing first quarter of 2023 financial report, where Revenue melted down by -35.588 % to $56.90 million and the In Vitro and In Vivo Diagnostic Substances company posted net deficit per share to $-0.68, in contrast to $0.35, in the financial interval ending December 31 2021. On the contrary to the In Vitro and In Vivo Diagnostic Substances company's scenario the on averageIn Vitro and In Vivo Diagnostic Substances industry, posted a top-line 27.43% improvement compared to the comparable period a year before in the first quarter of 2023.

Biomerica Inc

Biomerica Inc: Losses Narrow but Revenue Plummets Amid Investor Concerns for Future Performance

Biomerica Inc Faces Challenges as Revenue Falls and Losses Widen
Investors in Biomerica Inc are facing a challenging period, as the company reported a decline in revenue and widening losses for the March to May 31, 2023 time-frame. The company's financial performance has raised concerns among investors who are now questioning the future prospects of the company.
In terms of earnings per share, Biomerica Inc managed to improve, with a loss per share decreasing from $-0.14 to $-0.10 compared to the previous year. However, the company's revenue fell sharply by -79.099% from $5.30 million to $1.11 million, indicating a significant decline in sales for the comparable reporting season. Sequentially, revenue also decreased by -0.291%.

Quotient Limited

The In Vitro and In Vivo Diagnostic Substances company announced that revenue decreased softly , during the third quarter of 2023 earnings season

Lower revenue led to diminishing Returns in the October to December 31 2022 time-frame, Revenue diminished by -4.405 % to $9.05 million and deficit per share was at $-3.13 in contrast to $-0.28 per share realized in the quarter a year before. In contrast to the the Quotient Limiteds' scenario the rest ofIn Vitro and In Vivo Diagnostic Substances sector, posted a top-line 27.43% rise compared to the same period a year before in the third quarter of 2023.

Oncocyte Corporation

Oncocyte Corporation Stumbles as Revenues Plummet 57.562% in Q2 2023, Raising Investor Alarm

In the wake of the most recent fiscal period, Oncocyte Corporation has unveiled concerning financial results, reporting a drastic decline in revenue and a significant increase in net loss per share. While the rest of the In Vitro and In Vivo Diagnostic Substances sector saw positive growth, Oncocyte Corporation struggled to maintain its foothold. This article seeks to shed light on the implications of the company's performance and its contrasting market sentiment.
Revenues and Net Loss Per Share:
Oncocyte Corporation's revenues plummeted by an alarming 57.562% to a mere $0.46 million in the most recent fiscal period. This decrease is significant, especially when compared to the corresponding financial report from the previous year. The net loss per share also stands out, swelling to $-1.07, further amplifying concerns among investors.

Neogen Corporation

Neogen Corporation Achieves Remarkable 72.256% Revenue Surge Throughout Q1-Q2 2023

Over the past five trading days, the stock of Neogen Corporation has experienced a decline of -4.7%. This brings the year-to-date performance of the stock to 47.44%. Additionally, the stock is currently 6.6% short off its 52-week high.
In its May 31, 2023 report, Neogen Corporation announced a net profit per share of $0.02 and revenue of $218.26 million. This reflects a sharp decline in income compared to the fourth quarter of 2022 when the company earned $0.14 EPS. However, during the same period, revenue rose by an impressive 72.256%. Neogen Corporation has clearly outperformed its peers in the In Vitro and In Vivo Diagnostic Substances sector, which only showed 12.35% revenue growth during this time.


Meridian Bioscience Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com